Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740061 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL14739816 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL14740296 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL14740248 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL14739515 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL14739086 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL15836237 | 1.00 | GRIA1 (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL12090531 | 0.97 | POLB (0.52) | GRIA1POLBPPARAALDH1A1CA1 | |
| SCHEMBL11335730 | 0.89 | PPARA (0.64) | PPARACA1CA2CA12CA7 | |
| SCHEMBL2694822 | 0.89 | PPARA (0.64) | PPARACA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562183-B2 | Use of compounds with nitrogen-containing functional groups for thermal energy storage | ARKEMA FRANCE (FR) | 2017-02-07 | — | — | US | disclosed |
| US-20130056175-A1 | USE OF COMPOUNDS WITH NITROGEN-CONTAINING FUNCTIONAL GROUPS FOR THERMAL ENERGY STORAGE | ARKEMA FRANCE (FR) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130056175-A1 | USE OF COMPOUNDS WITH NITROGEN-CONTAINING FUNCTIONAL GROUPS FOR THERMAL ENERGY STORAGE | S100A4, NUCB2, C9 | GRIA1 4552/4885POLB 2662/4885PPARA 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.